A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201

被引：38
|
作者：
Loehrer, P. J., Sr.
Powell, M. E.
Cardenes, H. R.
Wagner, L.
Brell, J. M.
Ramanathan, R. K.
Crane, C. H.
Alberts, S. R.
Benson, A. B., III
机构：
[1] Indiana Univ, Eastern Cooperat Oncol Grp, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Case Western Reserve Univ, Cleveland, OH 44106 USA
[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.4506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4506
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
    Heinrich, Stefan
    Pestalozzi, Bernhard
    Lesurtel, Mickael
    Berrevoet, Frederik
    Laurent, Stephanie
    Delpero, Jean-Robert
    Raoul, Jean-Luc
    Bachellier, Phillippe
    Dufour, Patrick
    Moehler, Markus
    Weber, Achim
    Lang, Hauke
    Rogiers, Xavier
    Clavien, Pierre-Alain
    BMC CANCER, 2011, 11
  • [32] Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
    Stefan Heinrich
    Bernhard Pestalozzi
    Mickael Lesurtel
    Frederik Berrevoet
    Stéphanie Laurent
    Jean-Robert Delpero
    Jean-Luc Raoul
    Phillippe Bachellier
    Patrick Dufour
    Markus Moehler
    Achim Weber
    Hauke Lang
    Xavier Rogiers
    Pierre-Alain Clavien
    BMC Cancer, 11
  • [33] Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial
    Cascinu, Stefano
    Berardi, Rossana
    Bianco, Roberto
    Bilancia, Domenico
    Zaniboni, Alberto
    Ferrari, Daris
    Mosconi, Stefania
    Spallanzani, Andrea
    Cavanna, Luigi
    Leo, Silvana
    Negri, Francesca
    Beretta, Giordano D.
    Sobrero, Alberto
    Banzi, Maria
    Morabito, Alberto
    Bittoni, Alessandro
    Marciano, Roberta
    Ferrara, Domenica
    Noventa, Silvia
    Piccirillo, Maria C.
    Labianca, Roberto
    Mosconi, Cristina
    Gardini, Andrea Casadei
    Gallo, Ciro
    Perrone, Francesco
    EUROPEAN JOURNAL OF CANCER, 2021, 148 : 422 - 429
  • [34] A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
    Lee, Hee Seung
    Chung, Moon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Park, Seung Woo
    Kim, Ho Gak
    Noh, Myung Hwan
    Lee, Sang Hyub
    Kim, Yong-Tae
    Kim, Hyo Jung
    Kim, Chang Duck
    Lee, Dong Ki
    Cho, Kwang Bum
    Cho, Chang Min
    Moon, Jong Ho
    Kim, Dong Uk
    Kang, Dae Hwan
    Cheon, Young Koog
    Choi, Ho Soon
    Kim, Tae Hyeon
    Kim, Jae Kwang
    Moon, Jieun
    Shin, Hye Jung
    Song, Si Young
    MEDICINE, 2017, 96 (01)
  • [35] Meta-analysis of gemcitabine and cisplatin combination chemotherapy versus gemcitabine alone for pancreatic cancer
    Huang, Diyu
    Fang, Jie
    Luo, Gaojian
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (05) : 104 - 108
  • [36] A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic canceraEuro
    O'Neil, B. H.
    Scott, A. J.
    Ma, W. W.
    Cohen, S. J.
    Aisner, D. L.
    Menter, A. R.
    Tejani, M. A.
    Cho, J. K.
    Granfortuna, J.
    Coveler, L.
    Olowokure, O. O.
    Baranda, J. C.
    Cusnir, M.
    Phillip, P.
    Boles, J.
    Nazemzadeh, R.
    Rarick, M.
    Cohen, D. J.
    Radford, J.
    Fehrenbacher, L.
    Bajaj, R.
    Bathini, V.
    Fanta, P.
    Berlin, J.
    McRee, A. J.
    Maguire, R.
    Wilhelm, F.
    Maniar, M.
    Jimeno, A.
    Gomes, C. L.
    Messersmith, W. A.
    ANNALS OF ONCOLOGY, 2015, 26 (09) : 1923 - 1929
  • [37] A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer (vol 16, pg 1639, 2005)
    Oettle, H
    Richards, D
    Ramanathan, RK
    van Laethem, JL
    Peeters, M
    Fuchs, M
    Zimmermann, A
    John, W
    Von Hoff, D
    Arning, M
    Kindler, HL
    ANNALS OF ONCOLOGY, 2006, 17 (03) : 535 - 535
  • [38] CATIONIC LIPOSOMAL PACLITAXEL IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH UNRESECTABLE PANCREATIC CANCER: A RANDOMIZED CONTROLLED PHASE II TRIAL
    Lohr, M.
    Graeven, U.
    Bodoky, G.
    Maerten, A.
    Lilla, C.
    Meyer, I
    Osinsky, D.
    Cwiertka, K.
    Foelsch, U.
    Lutz, M.
    ANNALS OF ONCOLOGY, 2009, 20 : 9 - 9
  • [39] A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin
    Daniel H. Palmer
    Deborah D. Stocken
    Helen Hewitt
    Catherine E. Markham
    A. Bassim Hassan
    Philip J. Johnson
    John A. C. Buckels
    Simon R. Bramhall
    Annals of Surgical Oncology, 2007, 14 : 2088 - 2096
  • [40] A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin
    Palmer, Daniel H.
    Stocken, Deborah D.
    Hewitt, Helen
    Markham, Catherine E.
    Hassan, A. Bassim
    Johnson, Philip J.
    Buckels, John A. C.
    Bramhall, Simon R.
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (07) : 2088 - 2096
12345